ArticleBlood advances2020
Association of ABO blood group with bleeding severity in patients with bleeding of unknown cause.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 50 citations in OpenAlex.
- Von Willebrand disease: A century of progress.Research and practice in thrombosis and haemostasis · 2026Review
- Abnormal whole-blood viscoelastic test results in patients with bleeding disorder of unknown cause.Blood vessels, thrombosis & hemostasis · 2026Article
- Integrative modeling to improve bleeding risk prediction in adult female hemophilia A carriers.Journal of thrombosis and haemostasis : JTH · 2026Observational
- Western Blot Detection of Blood Group A and B Antigens.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Glycan-binding specificities of anti-ABO(H) antibodies and lectins.Transfusion · 2026Article
- Impact of ABO Blood Group on Bleeding and Clotting Time Among Healthy North Indian Males: A Pilot Study.Cureus · 2025Article
- Clinical and Genetic Characterization of 51 Patients with Congenital Fibrinogen Disorders from China.Thrombosis and haemostasis · 2025Article
- Prevalence of iron deficiency in patients with mild to moderate bleeding disorders and bleeding disorder of unknown cause.Research and practice in thrombosis and haemostasis · 2025Article
- The relationship between ABO blood types and clopidogrel-related low on-treatment platelet reactivity in patients with coronary artery diseases and type 2 diabetes mellitus: a secondary analysis of a prospective cohort study.Diabetology & metabolic syndrome · 2025Article
- Loss of function in protein Z (PROZ) is associated with increased risk of ischemic stroke in the UK Biobank.Journal of thrombosis and haemostasis : JTH · 2025Article
- ABO blood type is not a risk factor of outcome in aneurysmal subarachnoid hemorrhage patients.European journal of medical research · 2024Article
- Impact of Additional Administration of von Willebrand Factor Concentrates to Thrombocyte Transfusion in Perioperative Bleeding in Cardiac Surgery.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2024Article
- Investigating patients for bleeding disorders when most of the "usual" ones have been ruled out.Research and practice in thrombosis and haemostasis · 2023Article
- Evaluation of Clinical Manifestations of Hemorrhoidal Disease, Carried Out Surgeries and Prolapsed Anorectal Tissues: Associations with ABO Blood Groups of Patients.Journal of clinical medicine · 2023Article
- Health-related quality of life is impaired in bleeding disorders of unknown cause: results from the Vienna Bleeding Biobank.Research and practice in thrombosis and haemostasis · 2023Article
- Impact of ABO blood group antigens on residual factor VIII levels and risk of inhibitor development in hemophilia A.Blood research · 2023Article
- Correlation between Blood Type 0 and Risk of Chronic Subdural Hematoma Recurrence: A Single Center Retrospective Cohort Study.Brain sciences · 2023Article
- Clinical Predictors and Prediction Models for rFVIII-Fc Half Life in Real-World People with Severe Hemophilia A.Journal of clinical medicine · 2023Article
- Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency.Journal of thrombosis and haemostasis : JTH · 2023Article
- ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies.iScience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood group O has been associated with an increased bleeding tendency due to lower von Willebrand factor (VWF) and factor VIII (FVIII) levels. We explored whether blood group O is independently associated with bleeding severity in patients with mild-to-moderate bleeding of unknown cause (BUC) in the Vienna Bleeding Biobank cohort. Bleeding severity was recorded with the Vicenza bleeding score (BS). Blood group O was overrepresented in 422 patients with BUC compared with its presence in 23 145 healthy blood donors (47.2% vs 37.6%; odds ratio, 1.48; 95% confidence interval [CI], 1.22-1.79). The BS and the number of bleeding symptoms were significantly higher in patients with blood group O than in patients with non-O after adjustment for VWF and FVIII levels and sex (least-square [LS] means of BSs: 6.2; 95% CI, 5.8-6.6 vs 5.3; 4.9-5.7; and of number of symptoms: LS, 3.5; 95% CI, 3.2-3.7 vs 3.0; 2.8-3.2, respectively). Oral mucosal bleeding was more frequent in those with blood group O than in those with other blood types (group non-O; 26.1% vs 14.3%), independent of sex and VWF and FVIII levels, whereas other bleeding symptoms did not differ. Patients with blood group O had increased clot density in comparison with those with blood group non-O, as determined by rotational thromboelastometry and turbidimetric measurement of plasma clot formation. There were no differences in thrombin generation, clot lysis, or platelet function. Our data indicate that blood group O is a risk factor for increased bleeding and bleeding severity in patients with BUC, independent of VWF and FVIII levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.